Ongoing challenges of using immunotherapy in special populations: poor performance status patients, elderly patients, and people living with HIV
Immunotherapy with immune checkpoint inhibitors (ICIs) represents a breakthrough in lung cancer treatment. The efficacy of monoclonal antibodies targeting the programmed cell death protein 1 (PD-1), its ligand L1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) pathways has been demonstrated in several randomized trials, at first as second line therapy, then as first line with or without combination with chemotherapy, resulting in significantly improved survival rates in lung cancer patients, especially those with advanced non-small-cell lung cancer (NSCLC), compared to standard chemotherapy.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Val érie Gounant, Armelle Lavolé, Elisabeth Quoix Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer